{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:19:07Z","timestamp":1779236347149,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clim.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T11:30:21Z","timestamp":1502710221000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The unmet need in rheumatology: Reports from the targeted therapies meeting 2017"],"prefix":"10.1016","volume":"186","author":[{"given":"Kevin L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Crow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Melchers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand C.","family":"Breedfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Kalden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.clim.2017.08.009_bb0005","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.clim.2017.08.009_bb0015","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2017.08.009_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"4 Suppl. 98","key":"10.1016\/j.clim.2017.08.009_bb0025","first-page":"69","article-title":"The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016","volume":"34","author":"Winthrop","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.clim.2017.08.009_bb0035","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/rheumatology\/kew210","article-title":"Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register","volume":"55","author":"Cook","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18553\/jmcp.2016.14261","article-title":"Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis","volume":"22","author":"Hopson","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"7","key":"10.1016\/j.clim.2017.08.009_bb0045","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00296-015-3222-4","article-title":"Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review","volume":"35","author":"Ferriols-Lisart","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.clim.2017.08.009_bb0050","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization-a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.clim.2017.08.009_bb0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/odi.12472","article-title":"The microbiome systemic diseases connection","volume":"22","author":"van der Meulen","year":"2016","journal-title":"Oral Dis."},{"issue":"6","key":"10.1016\/j.clim.2017.08.009_bb0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.berh.2016.02.001","article-title":"Refine, reduce, replace: imaging of fibrosis and arthritis in animal models","volume":"29","author":"Marenzana","year":"2015","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2017.08.009_bb0065","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"Dorner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clim.2017.08.009_bb0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrrheum.2017.79","article-title":"Biosimilar switching: \u201cto set a form upon desired change\u201d","volume":"13","author":"Kay","year":"2017","journal-title":"Nat. Rheumatol. Rev."},{"key":"10.1016\/j.clim.2017.08.009_bb0075","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.160904","article-title":"Updating the Psoriatic Arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016","author":"Orbai","year":"2017","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2016.1139453","article-title":"Psoriatic arthritis: complexities, comorbidities and implications for the clinic","volume":"12","author":"Haroon","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12016-016-8529-8","article-title":"Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review","volume":"51","author":"Sukhov","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"Suppl. 11","key":"10.1016\/j.clim.2017.08.009_bb0090","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0095","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","article-title":"Etiology and pathogenesis of psoriatic arthritis","volume":"41","author":"Barnas","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/BOR.0000000000000187","article-title":"The intestinal microbiome in spondyloarthritis","volume":"27","author":"Gill","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"Suppl. 10","key":"10.1016\/j.clim.2017.08.009_bb0115","article-title":"Safety and efficacy of ABT-122, a TNF and IL-17\u2013targeted dual variable domain (DVD)\u2013Ig\u2122, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial [abstract]","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00296-015-3377-z","article-title":"Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review","volume":"36","author":"Cobo-Ibanez","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-011-1172-6","article-title":"Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic","volume":"304","author":"Velez","year":"2012","journal-title":"Arch. Dermatol. Res."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ca.22519","article-title":"Morphological and biomechanical analyses of the subchondral mineralized zone in human sacral facet joints: application to improved diagnosis of osteoarthritis","volume":"28","author":"Berteau","year":"2015","journal-title":"Clin. Anat."},{"issue":"26","key":"10.1016\/j.clim.2017.08.009_bb0135","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clim.2017.08.009_bb0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","article-title":"The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis","volume":"75","author":"Deodhar","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.08.009_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fimmu.2016.00035","article-title":"Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE","volume":"7","author":"Mahajan","year":"2016","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2017.08.009_bb0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.clim.2017.08.009_bb0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1759720X15601805","article-title":"Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications","volume":"7","author":"Jordan","year":"2015","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2017.08.009_bb0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-016-8534-y","article-title":"Critical link between epigenetics and transcription factors in the induction of autoimmunity: a comprehensive review","volume":"50","author":"Wu","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"16","key":"10.1016\/j.clim.2017.08.009_bb0170","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.08.009_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23201","article-title":"Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls","author":"Aberle","year":"2017","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.clim.2017.08.009_bb0180","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","article-title":"Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies","volume":"74","author":"Lu","year":"2016","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.clim.2017.08.009_bb0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.40004","article-title":"Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features","volume":"69","author":"Munroe","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2017.08.009_bb0195","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2017.08.009_bb0205","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0961203316636468","article-title":"A liposomal steroid nano-drug for treating systemic lupus erythematosus","volume":"25","author":"Moallem","year":"2016","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.rdc.2016.01.001","article-title":"Patient-reported outcomes in systemic lupus erythematosus","volume":"42","author":"Mahieu","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"7","key":"10.1016\/j.clim.2017.08.009_bb0215","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3899\/jrheum.161202","article-title":"Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematosus","volume":"44","author":"Kasturi","year":"2017","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcph.591","article-title":"Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy","volume":"56","author":"Lee","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.clim.2017.08.009_bb0235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1358\/dot.2010.46.12.1543301","article-title":"An overview of pharmacotherapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"46","author":"Stasi","year":"2010","journal-title":"Drugs Today (Barc.)"},{"issue":"2","key":"10.1016\/j.clim.2017.08.009_bb0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0000000000000145","article-title":"Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"27","author":"Flint","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/BOR.0000000000000135","article-title":"Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis","volume":"27","author":"Tomasson","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2017.08.009_bb0250","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BOR.0000000000000129","article-title":"Outcome measures for Takayasu's arteritis","volume":"27","author":"Aydin","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"Suppl. 10","key":"10.1016\/j.clim.2017.08.009_bb0255","article-title":"Tocilizumab for the treatment of giant cell arteritis \u2013 a randomized placebo-controlled trial [abstract]","volume":"67","author":"Adler","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0260","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"21","key":"10.1016\/j.clim.2017.08.009_bb0265","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1097\/MD.0000000000003785","article-title":"Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Hao","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.clim.2017.08.009_bb0270","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/art.39686","article-title":"Immunoglobulin G4-related disease: retrospective analysis of 166 patients","volume":"68","author":"Sekiguchi","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2017.08.009_bb0275","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"25","key":"10.1016\/j.clim.2017.08.009_bb0280","doi-asserted-by":"crossref","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617305430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617305430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T15:20:22Z","timestamp":1535469622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617305430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":55,"alternative-id":["S1521661617305430"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.08.009","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The unmet need in rheumatology: Reports from the targeted therapies meeting 2017","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}